KEGG   DRUG: TadocizumabHelp
Entry
D06649                      Drug                                   

Name
Tadocizumab (USAN)
Formula
C2107H3252N562O673S12
Exact mass
47579.417
Mol weight
47608.5074
Sequence
(A chain) QVQLVQSGAE VKKPGSSVKV SCKASGYAFT NYLIEWVRQA PGQGLEWIGV
IYPGSGGTNY NEKFKGRVTL TVDESTNTAY MELSSLRSED TAVYFCARRD GNYGWFAYWG
QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH
TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTH
(Disulfide bridge: 22-96; 146-202 Dimer: A222-B214)
(B chain) DIQMTQTPST LSASVGDRVT ISCRASQDIN NYLNWYQQKP GKAPKLLIYY
TSTLHSGVPS RFSGSGSGTD YTLTISSLQP DDFATYFCQQ GNTLPWTFGQ GTKVEVKRTV
AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD
STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: 23-88; 134-194)
  Type
Peptide
Activity
Platelet aggregation inhibitor, Anti-glycoprotein IIb/IIIa antibody
Comment
Monoclonal antibody
Treatment of patients undergoing percutaneous coronary interventions
Target
  Pathway
Focal adhesion
ECM-receptor interaction
Brite
Target-based classification of drugs [BR:br08310]
 Others
  Cell adhesion molecules (CAMs)
   glycoprotein alpha IIb/beta3 (GPIIb/IIIa) receptor
    Tadocizumab
     D06649  Tadocizumab (USAN)
BRITE hierarchy
Other DBs
CAS: 
339086-80-5
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system